- Novavax ( NASDAQ: NVAX ) announced an agreement with the U.S. government on Monday under which the Maryland-based biotech will initially supply 3.2M doses of its COVID-19 vaccine subject to its FDA authorization and CDC clearance.
- The agreement with the U.S. Department of Health and Human Services ( HHS ), in collaboration with the Department of Defense, will add the first protein-based COVID-19 shot for the country’s immunization drive.
- "We are pleased to come one step closer to potentially offering our vaccine to physicians, healthcare organizations, and consumers who have been awaiting a protein-based vaccine option," Chief Executive Stanley C. Erck noted.
- Last month, an advisory committee of the federal agency voted to recommend the emergency authorization for the NVX-CoV2373 vaccine for the prevention of COVID-19 in those aged 18 years and older.
For further details see:
Novavax to deliver 3.2M doses of COVID-19 vaccine to U.S.